The U.S. Food and Drug Administration (FDA) has twice rejected Replimune Group Inc.'s experimental melanoma drug, RP1 (vusolimogene oderparepvec), citing significant concerns regarding its study design. The Wall Street Journal reported that the agency questioned the methodology of the clinical trials, leading to two denials for the oncolytic immunotherapy. This decision has sparked debate within the medical community and the pharmaceutical industry, particularly given the urgent need for new treatments for advanced melanoma.
Replimune's RP1, an engineered herpesvirus designed to stimulate the immune system against cancer, was proposed for use in combination with nivolumab (Opdivo) for patients with advanced cutaneous melanoma. The Biologics License Application was primarily supported by data from the single-group phase 1/2 IGNYTE clinical trial. However, the FDA's Complete Response Letters indicated that the data provided insufficient evidence of effectiveness, specifically highlighting the lack of a control arm in the trial design.
The FDA's stance has drawn criticism, with some oncologists and patient advocates expressing disappointment over the delays in approving a potentially life-extending treatment. Former FDA Commissioner Marty Makary, whose tenure saw the second rejection in April 2026, defended the agency's decision, accusing Replimune of "corporate spin" and asserting that the FDA "stands by the scientists." A Wall Street Journal editorial assailed the ruling, suggesting it could have a "chilling effect on drug development."
Melanoma remains a significant public health challenge, with approximately 110,000 new cases diagnosed annually in the U.S., and treatment options for advanced stages are limited. The five-year survival rate for metastatic melanoma drops to roughly 16 percent, underscoring the critical need for innovative therapies like RP1. Despite the benefits observed in some patients, the FDA maintained that robust trial designs are essential for regulatory approval.
In a recent development, Replimune announced plans to resubmit its melanoma drug for approval following a leadership transition at the FDA. The company stated that constructive dialogue with the agency represents an important step forward for patients with advanced melanoma who have progressed on prior anti-PD-1 based therapies. This upcoming resubmission will be closely watched by stakeholders eager for new treatment avenues.
